Lantern Pharma Inc. has entered into a research collaboration with Bielefeld University to develop antibody-drug conjugates (ADCs) with therapeutic and antitumor potential. Using Lantern’s proprietary artificial intelligence (AI) platform, RADR, the collaboration will leverage insights from the recently developed RADR AI ADC module in combination with research from Bielefeld.
Pipeline Therapeutics Inc. has received FDA clearance to initiate a phase I trial of PIPE-791 in healthy volunteers, with dosing expected to begin in the second half of this year. PIPE-791 is advancing toward clinical development for remyelination and neuroinflammation, with a leading indication of multiple sclerosis (MS).
Wigen Biomedicine Technology (Shanghai) Co. Ltd. researchers have identified mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
AC Immune SA has patented 4h-imidazo[1,5-b]pyrazole derivatives and labeled compounds targeting α-synuclein (SNCA). They are reported to be useful for diagnosis of multiple system atrophy, Parkinson’s dementia, Lewy body dementia, Alzheimer’s and Parkinson’s disease, among others.
Cerevance Inc. has described N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors. As such, they are reported to be useful for the treatment of aging, diabetic nephropathy, glaucoma, inflammatory disorders, metabolic syndrome, obesity and rheumatoid arthritis.
Research at the University of California, Oakland and 1200 Pharma LLC has led to the identification of GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
Allianthera (Suzhou) Biopharmaceutical Co. Ltd. has patented new aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of cancer, lung diseases, bone, dermatological, eye, gastrointestinal, neurological and pancreatic disorders, among others.
Tuberculosis (TB) is the 13th leading cause of death in the world, and it is rising together with the increased prevalence of drug-resistant TB in many countries. The Bacille Calmette-Guerin (BCG) vaccine is the only available TB vaccine, and it has been given to more people than any other vaccine. While the BCG vaccine has saved tens of millions of lives, it confers suboptimal protection against pulmonary TB as it is limited to providing protection only until early childhood. Significantly, the BCG vaccine is administered intradermally to confer exceptional mucosal immunity as compared to most other vaccines, which are more commonly administered intramuscularly. Novel strategies to improve the duration of TB mucosal immunity are urgently needed.
Iktos SA and Curreio Inc. have established a collaboration agreement using artificial intelligence (AI) for new drug design. Under this collaboration, Iktos will leverage its de novo generative design technology in combination with Curreio’s cryo-electron microscopy (EM) platform to facilitate the rapid design of novel preclinical drug candidates for an undisclosed target.
Researchers from Universität zu Köln have published data from a study that investigated the pathophysiology of disabling pansclerotic morphea (DPM), and as such, gain better understanding of the much larger range of disorders characterized by poor wound healing and severe, unchecked fibrosis.
RSS
